In several preclinical studies, inhibition of GSH or Trx antioxidant systems, downstream of Nrf2 signaling, has been demonstrated to sensitize different types of tumor cells towards radiotherapy [55,56,57]. This evidence concerns the gene TXN and neoplasm.